Sunday, July 31, 2011

Diabetic retinopathy is the leading cause of blindness in patients between 25 and 74 years old, according to the study appearing online in the journal General Hospital Psychiatry.

The study, as per the authors, while controling for obesity, smoking, sedentary lifestyle and HbA1c levels, found that increased risk of retinopathy in those patients who are depressed. The authors studied 2,359 patients with diabetes enrolled in the Pathways Epidemiologic Study and assessed their levels of depression using the Patient Health Questionnaire-9 (PHQ-9), a self-reported survey of depression symptoms.

Over the five-year follow-up period, 22.9 percent of the patients who had PHQ-9 scores that ranked as “major depression” developed diabetic retinopathy, compared with 19.7 percent of the patients without depression. With a five-point increase on the PHQ-9 score, patients’ risk of having diabetic retinopathy increased by up to 15 percent.

The authors conclude that changes associated with depression such as increased cortisol levels and the activity of blood-clotting factors may be linked to the development of retinopathy in patients who are depressed. They also add that multiple explanations might account for these findings, with some of them related to biological changes and others to behavioral social issues, such as decreased physical activity and poorer utilization of health care.

The question that arises is whether identifying and treating depression in patients with diabetes will make a difference to development or pregression of retinopathy.

If you wish to read the article, please click here.

Friday, July 15, 2011

Patients Undergo Embryonic Stem Cell Transplantation Treatment for Stargardt's Disease and Macular Degeneration

Advanced Cell Technology, Inc., a leading company in the field of regenerative medicine, has announced that two patients have been implanted with retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs) in each of its two Phase 1/2 clinical trials for Stargardt's macular dystrophy and dry age-related macular degeneration (AMD).

The patients were treated on July 12, 2011, at the David Geffen School of Medicine at UCLA's Jules Stein Eye Institute in Los Angeles, USA. Both patients successfully underwent the outpatient transplantation surgeries and are said to be recovering uneventfully.

One patient in each clinical trial, the Stargardt's trial and the dry AMD trial, underwent surgical transplantation of a small dose (50,000 cells) of fully-differentiated RPE cells derived from human embryonic stem cells. The patients appear to have tolerated the surgical procedures well.

Regarding the clinical trial:

Both the Stargardt's trial and the dry AMD trial will enroll 12 patients each, with cohorts of three patients each in an ascending dosage format. Both trials are prospective, open-label studies designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with Stargardt's and dry AMD at 12 months, the studies' primary endpoint.

This is the first step in the clinical trial, which will potentially define the dose required to help treat the condition. If the trial succeeds, it opens doors to a potentially significant and new therapeutic approach to treating Stargardt's disease and AMD.

The primary objective of these Phase 1/2 studies is to assess the safety and tolerability of these stem cell-derived transplants. The patients will be carefully monitored over the course of the trials, to observe and report for any untoward and adverse event that may happen.

To know more of this trial, please click here.

About hESC-RPE Cells

RPE cells are highly specialized tissue located between the choroid and the retina. RPE cells support, protect and provide nutrition for the light-sensitive photoreceptors. Human embryonic stem cells differentiate into any cell type, including RPE cells, and have a similar expression of RPE-specific genes compared to human RPE cells and demonstrate the full transition from the hESC state.

About Stargardt's macular dystrophy:

Stargardt's macular dystrophy is one of the most common forms of macular degeneration in the world. Stargardt's causes progressive vision loss, usually starting between 10 to 20 years of age. Eventually, blindness results from photoreceptor loss associated with degeneration in the pigmented layer of the retina, called the retinal pigment epithelium or RPE cell layer.

About Age-related Macular Degeneration:

Degenerative diseases of the retina are among the most common causes of untreatable blindness in the world. Approximately 10% of people ages 66 to 74 will have symptoms of macular degeneration, the vast majority of them suffering from the "dry" form of AMD - which is currently untreatable. The prevalence increases to 30% in patients 75 to 85 years of age.

Dry AMD, the most common form of macular degeneration, Stargardt's and other forms of atrophy-related macular degeneration are untreatable at this time, and need effective therapies for treatment of these common forms of blindness.

Disease progression of both Stargardt's and dry AMD includes thinning of the layer of RPE cells in the patient's macula, the central portion of the retina and the anatomic location of central vision. When RPE cells die, the macular photoreceptors are lost, leading to loss of central vision. This approach focuses on treating these conditions by transplanting RPE cells in the patient's eyes before the RPE population is lost.

Source

Tuesday, July 12, 2011

Market for Age-related Macular Degeneration and Diabetic Retinopathy Drugs Will Reach $5084m by 2014

A new report by visiongain, a London-based business information provider, predicts that the market for age-related macular degeneration (AMD) and diabetic retinopathy (DR) drugs will reach $5084m by 2014. This will make retinal diseases the most lucrative sector of the ophthalmic drugs market, overtaking the glaucoma sector.

The AMD and DR market generated $3173m in 2010, according to Macular Degeneration (AMD) and Diabetic Retinopathy (DR): World Drug Market 2011-2021, published in July 2011.

AMD and DR are retinal disorders that can lead to blindness. Between them, they have been the cause for over 13% of all blindness cases in the world, according to a most recent WHO assessment. Both AMD and DR will become more widespread in the coming decades, as the world's population ages and the global diabetes epidemic continues.

Genentech's development of Lucentis (ranibizumab) made the 'wet' form of AMD effectively treatable for the first time. The success of Lucentis spurred investment in R&D for retinal diseases. In 2011, new products for wet AMD, as well as treatments for the 'dry' form of AMD, and for DR and diabetic macular oedema, are all nearing approval.

August will see the approval of Eylea (aflibercept), Regeneron Pharmaceuticals' new AMD treatment. This will be the most important new product in the AMD and DR sector since the launch of Lucentis.

Visiongain's research suggests that scientific study of retinal diseases will yield more important insights in the next ten years. While Lucentis and Eylea target vascular endothelial growth factor (VEGF), products with new targets will gain importance as monotherapies and in combination with VEGF inhibitors.

Visiongain predicts that the AMD and DR market will grow steadily to 2021, with treatments for dry AMD and DR answering the serious unmet needs in the sector.

Source

First VIDION® ANV® Therapy System Utilization in Switzerland for the Treatment of Neovascular Age-Related Macular Degeneration

NeoVista, Inc. has announced the first commercial utilization of Epimacular Brachytherapy in Switzerland. Epimacular Brachytherapy is performed using the VIDION (R) ANV Therapy system and is being offered as an adjunct therapy to anti-VEGF injections for the treatment of neovascular or wet age-related macular degeneration.

Professor Dr. Marc D. de Smet, Professor and Head of the Retina Unit at the Montchoisi Clinic in Lausanne feels Epimacular Brachytherapy with VIDION® is a surgical procedure that is technically feasible in good hands, with minimal to no risks and reduces the burden of follow up and retreatments.

As per the company, NeoVista’s phase 2 clinical study results continue to highlight the potential benefits of utilizing radiation with anti-VEGF therapy in treating wet AMD – especially on smaller classic lesions and patients with pigment epithelial detachments. They believe that their treatment approach, Epimacular Brachytherapy, greatly reduces the number of anti-VEGF injections, while maintaining visual acuity – especially in those lesion subtypes that typically require a large number of injections."

NeoVista’s Phase 3 study, CABERNET, is about to conclude the required 2 year patient follow-up. The initial data from this study is scheduled to be presented during the upcoming AAO Retina Sub-Specialty Meeting in Orlando, Florida, October 21. The NeoVista approach to treating wet AMD delivers a focused and fixed dose of strontium 90 beta radiation directly to the back of the eye, without damaging the adjacent healthy retinal vasculature. Importantly for patients, the systemic exposure to radiation is easily tolerated and the energy is delivered in a highly controlled manner to a local area. The effective dose from this one-time treatment is less than that from a typical chest x-ray to the entire body.

Source

Some other articles on Epimacular Brachytherapy can be read here, here, here and here.

Tuesday, July 5, 2011

Sightseeing for blind people

By Jon Henley  /  The Guardian, London (click here for the original article)

So we’re standing in the street outside the brothel — or what used to be the brothel — in Pompeii. The one with the rude frescoes on the walls showing ancient Roman punters exactly what they could expect for their sesterces.

There are 20 of us, or thereabouts, and before we go in the man in the white cheesecloth shirt and the floppy sun hat would like a word.

“Ladies and gentlemen, our sighted guides,” says Amar Latif. “I’d just like to remind you of my words at the beginning of this holiday. You are not carers; you are fellow travelers, companions. And one of the most valuable things you can do is to describe in loving detail whatever you might see before you that is of visual interest. Here’s your chance.”

And so it is that Maggie Heraty, a jolly humanitarian logistics expert more used to organizing emergency relief operations in Liberia or Haiti, finds herself explaining to Jenny Tween, who works at the BBC and has optic atrophy, meaning she has been partially sighted since she was two, that here we have: “a gentleman, reclining. With a naked lady squatting on top.”

While over here, Heraty continues, undaunted by Tween’s snorts, we can see (or not, of course) “the doggy position. And just along from that, the lady’s on top of the gentleman, again. But facing his feet this time. Hmmm.” She pauses. “Sorry, Jenny. Just trying to work out the mechanics of that one. I don’t think I’ve ever tried it.”

It’s not, obviously, that these people spend their holiday discussing the sex lives of the Ancients.

But nor are they your regular holidaymakers. Half of them, for a start, are blind or visually impaired. The other half are fully sighted. The former have paid a bit more than they might do for a standard package holiday to come on this week-long break in Sorrento, southern Italy, including flights, transfers, half-board in a four-star hotel with pool, a cookery lesson and excursions to Pompeii, Capri and Positano.

The latter have paid quite a bit less. In exchange, every day they will take a different visually impaired traveler by the arm (not literally, there’s nothing a blind or partially sighted person — or “VI,” as they’re more familiarly known — loathes more than being patronized) and act as their guide. Show them, as it were, the sights.

Sighted travelers help VIs with obvious obstacles: curbs, low arches and doorways, busy roads, flights of stairs (“Step down. One more to go. That’s the bottom.”) They explain where the food is on a plate (“Chicken at three o’clock, peas at six”). And once in a while, they get to describe in loving detail the wall paintings in the Pompeii brothel.

It’s not hard. In fact it’s fun. You learn a lot. “You get to do things you wouldn’t normally do,” says Wendy Coley from Loughborough, England, a sighted veteran of many such expeditions. “Once, in China, they got to touch the terra-cotta warriors. Imagine. And the act of describing what you see ... You take in far more, somehow; see things in a very different way. It may sound silly, but going on holiday with blind people opens your eyes.”

It does. I tried it at Gatwick with Latif, the 36-year-old Glasgow-born entrepreneur who set up this strangely inspiring business seven years ago. Latif has been without 95 percent of his sight since his first year at university, thanks to an incurable eye condition called retinitis pigmentosa. He founded Traveleyes, as the company is called, because “no one was doing the kind of holiday I wanted to go on,” and as far as he knows it’s the only one of its kind in the world.

An airport, you very quickly realize, is not a great place to be a VI. Inexpertly piloted baggage trolleys, beeping electric buggies, non-speaking departure boards, too many people in too much of a hurry; a nightmare. And if you ask for help, Latif says, they “put you in a wheelchair. Blind people go mental. It’s a liability avoidance thing, but it’s so humiliating. Most of us are highly independent, and extremely competent. We don’t need wheelchairs.”

Technology has made life easier in recent years, he concedes: “Piece of piss, to be honest, compared to what it was.” His mobile phone responds to vocal commands (assuming it understands his accent, which isn’t always), and speaks to him when he taps it. Screen reading software means blind and visually impaired people can use applications from Gmail to Excel, and even get the newspaper read to them online.

But navigating a crowded airport is another matter. Latif has his white cane, essential when he has to “go freestyle.” But it’s just more comfortable, sometimes, to be led. So what you do is, you stand beside and just slightly in front of the VI you’re leading, and offer them your elbow. They grasp it lightly (“Clicking on,” Latif calls it), and off you go. A tad slower than you otherwise might, but not much.

It’s that leading arm that transmits the messages. You have to talk, too, obviously, but it’s mainly just natural, friendly chat, interspersed with the odd alert (“Step up. Escalator coming.) Blind people feel in control when they’re holding your elbow, and will let go if they get anxious (or so says How to be a Sighted Traveler, the leaflet Traveleyes sends to its sighted customers).

You notice, too, that blind people pick up an awful lot more than you do through their other senses. “I can hear the hand-dryers,” says Latif. “Is that the gents, by any chance? Might just nip in.” Or, to a slightly nonplussed security man, “I can smell fruit. Exotic? Strawberries?” A fresh stick of Juicy Fruit gum, the guard admits.

You have to be a bit careful what you say, but you soon learn that an inadvertent “Did you see that?” or “Look, over there!” is not going to upset anyone.

Latif’s beaming presence helps hold the whole thing together. He’s a quite remarkable man; much in demand as a motivational speaker, and you can see why. A maths and finance graduate, he worked as a management accountant for eight years before striking out on his own, overcoming untold obstacles to launch a highly successful company, win a fistful of business and disability awards, and gladhand presidents and prime ministers.

“This holiday,” he announces to all on the bus from Naples airport to Sorrento, “is all about enjoying things on an equal basis. So if you’re blind, don’t worry, so am I. And if you’re sighted, don’t be so bloody clever.”

When it comes to holidays, beyond imposing again on long-suffering friends and relatives, the blind or visually impaired have shockingly few options. A charity called Vitalise runs holidays for people with a range of disabilities, but that’s about it. Not just in Britain, either: 30 percent of Traveleyes’ VIs come from abroad, mainly North America, Australia and New Zealand.

On the way back through town, stopping to wonder at the heft of a tomato and inhale an olive oil in the market, we’re drawn into a shop selling limoncello, the lemon-based liqueur of the Gulf of Naples. Sensing a celebratory mood, the proprietor turns up the music. “Here we say: we have a lemon, we have a girl, we have a party!” he proclaims. And to Dean Martin belting out Volare, then That’s Amore, everyone — unembarrassed — dances.

For sighted travelers, the motivation for this kind of holiday is maybe more complex. There are two sighted couples on this trip, but many are single. Several have tried singles holidays, without enjoying them: too full of “people out for themselves”; you end up “feeling lonelier when you leave than when you arrived.”
Irene Sylvester, from Wakefield in West Yorkshire, is newly retired. “I was looking for something I could do on my own,” she says, “but that wouldn’t make me feel I was on my own.” Jayn Bond, an HR and employment law specialist from Cambridge, wanted “a holiday that wouldn’t make me feel lonely, and where I could contribute.”

Others have less exalted reasons: Glyn Evans, a signalman from Rotherham, has been on a dozen Traveleyes holidays. He loves “the laughs. They’re great people.”

He’s on to something here, Latif, that’s about more than offering holidays for blind people. He knew the idea would work as soon as he tried it out for himself, with a student who used to read his textbooks for him at university: both of them had a ball. The first organized holiday, to a farmhouse in Andalucia, Spain, in 2004, was a roaring success; since then, Traveleyes has grown by 50 percent each year. And more than 60 percent of its business is repeat, from people who’ve been before.

Are there never problems? “You might think,” he says, “that the cheap holiday thing could attract the wrong people. We do a criminal records check and an employer’s check; it’s slightly tricky — you’re not employing people, but you do have to be aware that they’re dealing with vulnerable adults. But honestly, there’s never been a problem.”

Destinations are chosen carefully; there has to be plenty of opportunity for non-visual exploration. But blind people also love sightseeing, Latif insists. “The fact I can’t see the sights only heightens my curiosity,” he says.
It’s not uncommon, Latif says, for guests staying in the same hotel to ask whether they can join a Traveleyes group, “because they’ve seen the time we’re having, the atmosphere.” So what actually is happening here? A married couple, Dick and Lizzie Bulkely, turned away at the last minute by another firm because of Lizzie’s advancing glaucoma, put their finger on it.

“I’m really interested in how these groups work and get on,” says Dick, a retired clinical psychologist. “The constant negotiating, the compromise, the concern. There are real, important people skills going on here, all the time. I really like it. And you don’t come across it very often.”

New hope for diabetes treatment


Stem cells are now being used in medicine for a variety of disorders. These cells have become a source of great hope for a significant number of diseases in the regenerative medicine realm. They are also helping in the development of new drugs to prevent and treat such chronic and difficult to treat conditions such as Diabetes, Parkinson's disease, spinal cord injury and Macular Degeneration.

Dr. Ian Rogers, a Scientist at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, Canada, has been working on creating stem-cell based treatments for diabetes. He and his colleagues use stem cells to create natural replacements for essential cells in the pancreas that are destroyed by the illness, specifically in Type 1 diabetes.

For the past five years, Dr. Rogers has been focused on developing the regenerative capacity of umbilical cord and adult stem cells for clinical use, and making them a part of the future standard of care. His latest project involves developing induced pluripotent stem cells which have the ability to develop into many different types of cells from umbilical cord blood cells. Increasing the regenerative capacity of cord blood cells would extend their healing capacity beyond the blood diseases for which they are used currently.

For treatment of diabetes, the researchers differentiate stem cells into the critical cells of the pancreas that, in healthy people, measure blood sugar and produce the amount of insulin required to process it. These specialized cells would then be implanted in people with diabetes to reactivate the natural process.

At this stage, Dr. Rogers' team is building a pancreas out of a surgical sponge, in effect a three-dimensional structure seeded with insulin-producing islet cells. Ideally, the pancreas would be grown in the lab and then placed under the skin of a person with Type 1 diabetes to restore their insulin production.

This is a highly sophisticated procedure. The most advanced research project in his lab is much simpler: regenerating blood vessels so people with Type 2 diabetes who have damaged fingers and toes, (resulting from peripheral vascular disease) can avoid amputation.


So far the pancreatic stem cell technique has been studied in mice with promising results, although trials in humans are several years away. Lab studies have demonstrated that mice with a damaged pancreas can regulate their blood glucose levels within normal ranges with the transplanted cells. Coaxing the stem cells to develop into functional islets is not efficient enough to start clinical trials, but Dr. Rogers' group is now working to fix this problem.

It is known that stem cell transplants carry the risk of rejection or even possible tumour formation. To make the procedure safe, Dr. Rogers' lab is working to place the cells into porous bags that will allow the exchange of molecules between the cells and the body, but prevent the cells from escaping. This will also allow a physician to top up or replace the cells if they stop working.

The cells have shown no adverse side effects, hopefully demonstrating safety for future benefit in people with diabetes. If the procedure works, a patient's cell implants would require replacements every few years in an outpatient procedure, to counteract the body's natural immune response that slowly destroys them. Thus, instead of insulin injections, a patient would be using stem cell injections to augment his glucose levels. At first, the cells are expected to reduce the number of injections a patient requires. Eventually, as the procedure of generating islets becomes more efficient, the patient will be able to go for months or even years without having to inject insulin.

As the researchers note, there is considerable excitement of the potential for stem cell research but, ultimately, its value will only be realized if it can be applied to real medical needs. Dr. Rogers, like many other scientists around the world, is focused on developing this technology to ultimately benefit patients.

Source

Sunday, July 3, 2011

Development of new stem cell treatment for retinal diseases


The company ReNeuron has announced that it has signed a patent and know-how license agreement with Schepens Eye Research Institute, Boston, USA, regarding the Company’s ReN003 stem cell therapy programme focused on diseases of the retina.

An affiliate of Harvard Medical School, Schepens recently announced that it is to join forces with the MassachusettsEye and Ear Infirmary in Boston to create the world’s largest pre-clinical and clinical ophthalmology research centre.  ReNeuron has been collaborating with Schepens in the early development of its human retinal precursor cells (hRPCs).  Based on the successful results of this initial collaboration, the Company has, through this license agreement, secured the relevant intellectual property rights to develop and commercialise its hRPCs in the field of human retinal stem cell therapeutics.  ReNeuron will continue to collaborate closely with lead Investigator Dr Michael Young and his team at Schepens to take the Company’s ReN003 programme through late pre-clinical development and into an initial clinical trial in the US in patients suffering from retinitis pigmentosa, a blindness-causing disease caused by degeneration of the photoreceptor cells in the retina. 

Researchers at Schepens have already published data describing the ability of the hRPCs to integrate with host retinal tissue in rodent models of damaged retina and differentiate into the light-sensitive rod cells found in healthy retina.  Subsequently, a novel and highly efficient proprietary cell expansion process has recently been optimised which does not involve genetic modification or other similar manipulation of the hRPCs.  This expansion technology is currently being employed by ReNeuron to grow and bank clinical-grade hRPCs to the quantities required for future clinical studies.  

Subject to regulatory advice and the results of IND-enabling late pre-clinical studies, the ReN003 programme is expected to enter its clinical phase in approximately 18 months.  Importantly, although retinitis pigmentosa is the initial target disease, the hRPCs developed in the programme will almost certainly be applicable as cell therapy candidates for other blindness-causing diseases, such as age-related macular degeneration and diabetic retinopathy. 

Schepens Eye Research Institute fights blindness by developing new technologies, therapies and knowledge to preserve and restore vision. Through a continuum of discovery, the Institute works toward a future in which blindness is prevented, alleviated, and, ultimately, cured.

Founded in 1950 by famed retinal surgeon Charles L. Schepens, M.D., Schepens Eye Research Institute is the largest independent eye research institute in the United States and an affiliate of Harvard Medical School. Since its inception, the Institute has trained more than 600 postdoctoral fellows in various disciplines of eye research; trained more than 500 eye surgeons who now practice around the world; and published more than 4,600 scientific papers and books about health and eye disease.

About ReNeuron:
ReNeuron is a leading, clinical-stage stem cell business.  Its primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments.  ReNeuron’s lead candidate is its ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This therapy is currently in clinical development.  ReNeuron’s ReN009 stem cell therapy is being developed as a treatment for peripheral arterial disease, a serious and common side-effect of diabetes. The Company is also developing stem cell therapies for other conditions such as blindness-causing diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications – its ReNcell® products for use in academic and commercial research.  The Company’s ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

Saturday, July 2, 2011

Researchers invent new drug delivery device to treat diabetes-related vision loss


A team of engineers and scientists at the University of British Columbia has developed a device that can be implanted behind the eye for controlled and on-demand release of drugs to treat retinal damage caused by diabetes.

Diabetic retinopathy is the leading cause of vision loss among patients with diabetes. The disease is caused by the unwanted growth of capillary cells in the retina, which in its advanced stages can result in blindness.

The novel drug delivery mechanism is detailed in the current issue of Lab on a Chip, a multidisciplinary journal on innovative microfluidic and nanofluidic technologies.

The lead authors are recent PhD mechanical engineering graduate Fatemeh Nazly Pirmoradi, who completed the study for her doctoral thesis, and Mechanical Engineering Assoc. Prof. Mu Chiao, who studies nanoscience and microelectromechanical systems for biological applications. The co-authors are Prof. Helen Burt and research scientist John Jackson at the Faculty of Pharmaceutical Sciences.

A current treatment for diabetic retinopathy is laser therapy, which has side effects, among them laser burns or the loss of peripheral or night vision. Antiangiogenic drugs such as Lucentis & Avastin have also used to treat the disease. However, these compounds clear quickly from the bloodstream, which requires frequent and higher dosages, thus exposing other tissues to toxicity.

Key to this innovation is the ability to trigger the drug delivery system through an external magnetic field. The team accomplished this by sealing the reservoir of the implantable device – which is no larger than the head of a pin – with an elastic magnetic polydimethylsiloxane (silicone) membrane. A magnetic field causes the membrane to deform and discharge a specific amount of the drug, much like squeezing water out of a flexible bottle.

Click here for the schematic.

In a series of lab tests, the UBC researchers loaded the implantable device with the drug docetaxel and triggered the drug release at a dosage suitable for treating diabetic retinopathy. They found that the implantable device kept its integrity with negligible leakage over 35 days.

They also monitored the drug’s biological effectiveness over a given period, testing it against two types of cultured cancer cells, including those found in the prostate. They found that they were able to achieve reliable release rates.

As per the researchers, technologies currently available are either battery operated and are too large for treating the eye, or they rely on diffusion, which means drug release rates cannot be stopped once the device is implanted – a problem when patients’ conditions change. This device would offer controlled release of drug, depending on the status of the disease.

It will be several years before the device is ready for patient use. The researchers have a lot of work ahead in terms of proving biocompatibility as well as performance optimization. The team is also working to pinpoint all the possible medical applications for their device so that they can tailor the mechanical design to particular diseases.

From the UBC page.